摘要
目的:系统评价氨磷汀预防铂类神经毒性的临床疗效和安全性。方法:计算机检索Co-chrane图书馆、Pubmed、Embase、Cancerlit、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)和中文科技期刊全文数据库维普(VIP)、临床对照试验库,按照纳入与排出标准选择相关的随机对照试验,检索时间为1978年1月至2012年4月。在提取资料和评价质量后,用RevMan5.1.4软件进行Meta分析。结果:共纳入11个研究,合计949例患者,其中英文6篇,中文5篇。Meta分析结果显示:氨磷汀组能有效地减少神经毒性的发生[RR=0.57,95%CI(0.39,0.82),P=0.002],严重神经毒性的发生[RR=0.49,95%CI(0.29,0.84),P=0.009],加重呕吐的发生率[RR=1.36,95%CI(1.02,1.81),P=0.04],易发生低血压[RR=2.33,95%CI(1.29,4.23),P=0.005]。在恶心发生率[RR=1.20,95%CI(0.97,1.50),P=0.10]、头晕的发生率[RR=1.44,95%CI(0.50,4.12),P=0.50]上无统计学差异。结论:氨磷汀与铂类药物化疗时联合应用能有效地预防铂类神经毒性的发生,但会加重呕吐的发生,并容易产生低血压等不良反应。
AIM： To evaluate the efficacy and safety of amifostine in preventing platinum-induced neurotoxicity.METHODS： Retrieve from Cochrane Library,Pubmed,Emabase,Cancerlit,CBM,CNKI,VIP and Clinical Controlled Trials Database.Randomized controlled trials（RCT） were screened according to predefined inclusion and exclusion from the date of their establishment by april in 2012.Then the quality of the included trials was assessed and meta-analysis was performed by RevMan 5.1.4 software.RESULTS：A total of 11 studies involving 949 patients,six was English,while five was in Chinese.The resulted of meta-analyses showed that the experimental group was more effective than the control group in lowering the incidence of neurotoxicityP=0.002],the incidence of severe neurotoxicityP=0.009];increasing the incidence of vomitingP=0.04],the incidence of hypotentionP=0.005].There were no significant difference between the experimental group and the control group in increasing the incidence of neuseaP=0.10]and dizzinessP=0.50].CONCLUSION： Amifostine combine with platinum-based chemotherapy can effectively prevent the incidence of the neurotoxicity,but it will increase the incidence of vomiting and hypotention.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第10期1151-1156,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
